US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan.

ABSTRACT:

Background

Datopotamab deruxtecan (Dato-DXd) is an investigational antibody-drug conjugate that has shown promising results in phase III clinical trials of lung and breast cancers. Stomatitis is a common adverse event associated with Dato-DXd in these trials, and there are currently no formalized guidelines for its prevention and management. An expert consensus was needed to establish these guidelines.

Methods

Fifteen experts participated in a modified three-round Delphi to achieve consensus on the prevention and management of Dato-DXd-related stomatitis in lung and breast cancer patients. Fourteen experts had managed Dato-DXd-induced stomatitis and served as investigators in the TROPION-Lung01, TROPION-Lung05, and TROPION-Breast01 phase III clinical trials. The first two ro

SUBMITTER: Rugo H 

PROVIDER: S-EPMC12325563 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature